SCHEMBL2033231

SCHEMBL2033231

CCCCCCCCCC(C)CCCCCCCCC(=O)O[C@@H](CO)COP(=O)([O-])OCC[N+](C)(C)C

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 1/20 0.73
NR5A2 O00482 1/20 0.73
NR5A1 Q13285 1/20 0.73
RECQL P46063 1/20 0.68
MAPT P10636 3/20 0.64
ALDH1A1 P00352 1/20 0.60
ADRA1D P25100 1/20 0.58
PTAFR P25105 1/20 0.58
HTR1D P28221 1/20 0.58
HTR2C P28335 1/20 0.58
ADRA1B P35368 1/20 0.58
DRD3 P35462 1/20 0.58
TMEM97 Q5BJF2 1/20 0.58
FABP3 P05413 1/20 0.57
PLA2G1B P04054 1/20 0.56
PLA2G2A P14555 1/20 0.56
MAPK1 P28482 4/20 0.56
MEN1 O00255 2/20 0.56
GMNN O75496 2/20 0.56
LMNA P02545 2/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3404363 0.94 SMN1; SMN2 (0.82) SMN1; SMN2NR5A2NR5A1RECQLMAPT
SCHEMBL3409187 0.94 SMN1; SMN2 (0.82) SMN1; SMN2NR5A2NR5A1RECQLMAPT
SCHEMBL3406792 0.94 SMN1; SMN2 (0.82) SMN1; SMN2NR5A2NR5A1RECQLMAPT
SCHEMBL5058577 0.94 SMN1; SMN2 (0.82) SMN1; SMN2NR5A2NR5A1RECQLMAPT
SCHEMBL3407192 0.94 SMN1; SMN2 (0.82) SMN1; SMN2NR5A2NR5A1RECQLMAPT
SCHEMBL1270228 0.94 SMN1; SMN2 (0.82) SMN1; SMN2NR5A2NR5A1RECQLMAPT
SCHEMBL6287175 0.94 SMN1; SMN2 (0.82) SMN1; SMN2NR5A2NR5A1RECQLMAPT
SCHEMBL5052045 0.94 SMN1; SMN2 (0.82) SMN1; SMN2NR5A2NR5A1RECQLMAPT
SCHEMBL3404098 0.94 SMN1; SMN2 (0.82) SMN1; SMN2NR5A2NR5A1RECQLMAPT
SCHEMBL3408948 0.94 SMN1; SMN2 (0.82) SMN1; SMN2NR5A2NR5A1RECQLMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160161496-A1 Cells Having A Spectral Signature And Methods Of Preparation And Use Thereof Life Technologies Corporation 2016-06-09 US disclosed
US-20150198606-A1 METHOD FOR ENHANCING TRANSPORT OF SEMICONDUCTOR NANOCRYSTALS ACROSS BIOLOGICAL MEMBRANES CARNEGIE MELLON UNIVERSITY 2015-07-16 US disclosed
US-8993349-B2 Method for enhancing transport of semiconductor nanocrystals across biological membranes Life Technologies Corporation (US) 2015-03-31 US disclosed
EP-1700123-B1 METHOD FOR ENHANCING TRANSPORT OF SEMICONDUCTOR NANOCRYSTALS ACROSS BIOLOGICAL MEMBRANES LIFE TECHNOLOGIES CORP (US) 2013-09-11 EP disclosed
US-20110136139-A1 METHOD FOR ENHANCING TRANSPORT OF SEMICONDUCTOR NANOCRYSTALS ACROSS BIOLOGICAL MEMBRANES Life Technologies Corporation (US) 2011-06-09 US disclosed
EP-2085781-A1 Cells having a spectral signature, and methods of preparation and use thereof Life Technologies Corporation (US) 2009-08-05 EP disclosed
EP-1327145-B1 CELLS HAVING A SPECTRAL SIGNATURE, AND METHODS OF PREPARATION AND USE THEREOF LIFE TECHNOLOGIES CORP (US) 2009-03-11 EP disclosed
EP-1700123-A4 METHOD FOR ENHANCING TRANSPORT OF SEMICONDUCTOR NANOCRYSTALS ACROSS BIOLOGICAL MEMBRANES QUANTUM DOT CORP (US) 2007-09-19 EP disclosed
US-20070148634-A1 CELLS HAVING A SPECTRAL SIGNATURE AND METHODS OF PREPARATIONS AND USE THEREOF INVITROGEN CORPORATION (US) 2007-06-28 US disclosed
EP-1700123-A2 METHOD FOR ENHANCING TRANSPORT OF SEMICONDUCTOR NANOCRYSTALS ACROSS BIOLOGICAL MEMBRANES Quantum Dot Corporation (US) 2006-09-13 EP disclosed
WO-2005081721-A2 METHOD FOR ENHANCING TRANSPORT OF SEMICONDUCTOR NANOCRYSTALS ACROSS BIOLOGICAL MEMBRANES QUANTUM DOT CORPORATION (US) 2005-09-09 WO disclosed
US-20050059031-A1 Method for enhancing transport of semiconductor nanocrystals across biological membranes QUANTUM DOT CORPORATION 2005-03-17 US disclosed
US-20040023261-A1 Micelles comprising semiconductor nanocrystals and uses thereof Life Technologies Corporation 2004-02-05 US disclosed
EP-1327145-A2 CELLS HAVING A SPECTRAL SIGNATURE, AND METHODS OF PREPARATION AND USE THEREOF Quantum Dot Corporation (US) 2003-07-16 EP disclosed
US-20020155507-A1 Cells having a spectral signature, and methods of preparation and use thereof INVITROGEN CORP. 2002-10-24 US disclosed
WO-2002029410-A2 CELLS HAVING A SPECTRAL SIGNATURE, AND METHODS OF PREPARATION AND USE THEREOF QUANTUM DOT CORPORATION (US) 2002-04-11 WO disclosed